Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. The company faces significant financial challenges, evidenced by a low financial health score of 11/100, negative EBITDA and net margins, and a concerning current ratio of 0.61, indicating potential liquidity issues. While it has a gross margin of 25.3%, the overall financial performance raises concerns about sustainability and growth potential. The current market cap of $1.95M suggests that investor confidence may be low, reflecting the need for improved operational efficiency and profitability.
Loading financial metrics...
Company posted a loss of $-4.4M over the last year, representing 14.0% of revenue.
Strong revenue growth of 16.0% YoY indicates solid business momentum.
Strong balance sheet with net cash position provides cushion for growth investments.
Low debt-to-revenue ratio of 2.1% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q1 (September 30, 2025)